# nature portfolio

Corresponding author(s):	Daniel C Kirouac
Last updated by author(s):	Jan 16, 2023

## **Reporting Summary**

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

$\sim$				
<.	tat	ŀις	11	$\sim$

For	all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a	Confirmed
	The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement
$\boxtimes$	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	The statistical test(s) used AND whether they are one- or two-sided  Only common tests should be described solely by name; describe more complex techniques in the Methods section.
X	A description of all covariates tested
	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i> ) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
$\times$	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
X	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
	Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i> ), indicating how they were calculated
	Our was allestice as statistics for high sists particles as many of the points of our

#### Software and code

Policy information about <u>availability of computer code</u>

Data collection

Single cell RNA sequencing counts and associated metadata were retrieved from GEO (GSE197215 and GSE197268). Bulk RNA sequencing and associated metadata from Fraietta et al. (2018) was downloaded from the supplement, and all additional data was digitized from published figures using Graph Grabber v2 (Quintessa).

Data analysis

Model simulations and analysis were performed using Matlab R2021a and the SimBiology toolbox (6.1). All bioinformatics analysis was done on Ubuntu 20.04.3 LTS running R 4.1.1 ("Kick Things"). Key packages used were GSVA (1.40.1) for ssGSEA, fgsea (1.21.2) for GSEA, celldex (1.2.0) for obtaining reference datasets for SingleR (1.6.1), Seurat (4.1.0), data.table (1.14.2), limma (3.50.3), edgeR (3.34.1), Matrix (1.4.3) and ggplot2 (3.3.6) for data wrangling and visualization.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

#### Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

Provide	vour data	availability	stateme	nt here

### Human research participants

Policy information about studies involving human research participants and Sex and Gender in Research.

Reporting on sex and gender

Use the terms sex (biological attribute) and gender (shaped by social and cultural circumstances) carefully in order to avoid confusing both terms. Indicate if findings apply to only one sex or gender; describe whether sex and gender were considered in study design whether sex and/or gender was determined based on self-reporting or assigned and methods used. Provide in the source data disaggregated sex and gender data where this information has been collected, and consent has been obtained for sharing of individual-level data; provide overall numbers in this Reporting Summary. Please state if this information has not been collected. Report sex- and gender-based analyses where performed, justify reasons for lack of sex- and gender-based analysis.

Population characteristics

Describe the covariate-relevant population characteristics of the human research participants (e.g. age, genotypic information, past and current diagnosis and treatment categories). If you filled out the behavioural & social sciences study design questions and have nothing to add here, write "See above."

Recruitment

Describe how participants were recruited. Outline any potential self-selection bias or other biases that may be present and how these are likely to impact results.

Ethics oversight

Identify the organization(s) that approved the study protocol.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Field-specific reporting

|--|

ciences

Behavioural & social sciences

Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>

## Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size

all data used in this study was digitized from publications or downloaded, hence we had no control over clinical/experimental replicates. For stochastic algorithms (i.e. virtual population numbers, model fitting runs), sample sizes were chosen heuristically. That is, algorithms were run repeatedly at different depths to assess the stability of results. Iteration depths were then selected as those that generated consistent results while minimizing compute time. e.g. n=12 PSO runs at 100 particles x 100 iterations per-population, n=1000 virtual subjects per simulation, n=2500 classifier train/test split iterations.

Data exclusions

no data was excluded

Replication

computational replication was performed as described above to assess the stability of stochastic algorithms.

Randomization

computational randomization was performed where applicable to assess model predictions against null distributions. Parameter space scans to assess model goodness-of-fit, and random classification to assess predictive accuracy of the transcriptome classifier.

Blinding

Its not possible to perform computational analyses blinded.

## Reporting for specific materials, systems and methods

	_
	2
2	_ Τ
•	=
Ω	
-	_
	D
_	_
- (	
(	כ
	≒
2	
7	≺
- 2	_
	⇌
٠(	ر
=	
	_
-	7
-	D
7	_ D
7	T D
700	≒
- }	≒
-600	≒
700	≒
	≒
	≒
	≒
	≒
	≒
	≒
	≒
	≒
	≒

٥		
	⊱	
ž		
Ξ		
	Ξ	
	4	

Ма	terials & experimental systems	Methods	
n/a	Involved in the study	 n/a	Involved in the study
$\boxtimes$	Antibodies	$\boxtimes$	ChIP-seq
$\boxtimes$	Eukaryotic cell lines	$\boxtimes$	Flow cytometry
$\boxtimes$	Palaeontology and archaeology	$\boxtimes$	MRI-based neuroimaging
$\boxtimes$	Animals and other organisms		
$\times$	Clinical data		
$\boxtimes$	Dual use research of concern		

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.